Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

FDA approves Hernexeos, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option – Boehringer

Written by | 31 Mar 2026

The FDA approved Boehringer Ingelheim’s Hernexeos (zongertinib tablets) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase… read more.

Prostate cancer screening as good as breast cancer screening, say researchers

Written by | 21 Mar 2026

Prostate cancer screening compares favourably to screening for breast cancer in identifying significant cancers, reducing mortality and avoiding unnecessary harms, says new research. The findings are presented today… read more.

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Written by | 20 Mar 2026

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it will present… read more.

MHRA approves imlunestrant tosylate (Inluryo) for breast cancer – Eli Lilly

Written by | 20 Mar 2026

The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has approved imlunestrant tosylate (Inluriyo), a new treatment for adult patients with a certain type of breast… read more.

Zymeworks Announces Presentations for Ziihera (zanidatamab-hrii) at 2026 AACR Annual Meeting

Written by | 19 Mar 2026

The company’s partner, Jazz Pharmaceuticals, will present four abstracts featuring data from clinical trials evaluating Ziiher (zanidatamab-hrii) at the American Association for Cancer Research (AACR) Annual Meeting, being… read more.

Higher burnout rates among physicians who treat sickle cell disease

Written by | 18 Mar 2026

Hematology-oncology trained physicians who treat sickle cell disease reported higher rates of burnout (60%) than their counterparts who do not provide sickle cell care (43%) despite no differences in grit and resilience between the… read more.

Guardant Health to present 28 abstracts highlighting advances in tumor typing, therapy selection and expanded utility of multiomic tissue and liquid biopsy testing at AACR 2026

Written by | 18 Mar 2026

The company and its research collaborators will present 28 abstracts, including 3 oral sessions, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Association… read more.

CHMP adopts a positive opinion for Poherdy, a pertuzumab biosimilar for treatment of breast cancer – Organon

Written by | 16 Mar 2026

The Committee for Medicinal Products for Human Use (CHMP) of the EMA adopted a positive opinion, recommending the granting of a marketing authorisation for Poherdy in  combination with trastuzumab and… read more.

FDA grants full approval to Braftovi combination regimen in first-line metastatic colorectal cancer – Pfizer

Written by | 11 Mar 2026

Pfizer Inc. announced the  FDA has granted full approval to Braftovi (encorafenib) in combination with cetuximab (Erbitux ) and fluorouracil-based chemotherapy for the treatment of adult patients with… read more.

The Lancet Oncology: Breast cancer remains the most common cancer among women worldwide, with annual cases expected to reach over 3.5 million by 2050

Written by | 7 Mar 2026

Despite recent advancements in breast cancer treatments, new breast cancer cases in women are predicted to rise by a third globally from 2.3 million in 2023 to more than 3.5 million in 2050. Similarly, yearly deaths… read more.

Researchers create world’s largest dog and cat tumour database

Written by | 3 Mar 2026

Researchers from the University of Liverpool’s Veterinary Data Science Group and the University of Las Palmas de Gran Canaria have created the world’s largest open-source database of canine… read more.

Vir Biotechnology to present tolerability and anti-tumour signals for VIR-5500 in prostate cancer at ASCO GU 2026

Written by | 25 Feb 2026

Vir Biotechnology announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, Pro -xten dual-masked T-cell engager (TCE) being evaluated in… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.